Table 1.
Main baseline characteristics of the study population according to the presence or absence of 99mTc-DPD cardiac uptake
| Baseline characteristics | No cardiac 99mTc-DPD uptake (n = 178) | Cardiac 99mTc-DPD uptake (n = 114) | P-value |
|---|---|---|---|
| Male gender, n (%) | 134 (75) | 86 (75) | 0.98 |
| Age at diagnosis (years) | 69 ± 9 | 67 ± 9 | 0.07 |
| Supine systolic blood pressure (mmHg) | 116 ± 19 | 114 ± 18 | 0.38 |
| Disease duration (months) | 12 (6–18) | 9 (6–18) | 0.36 |
| NYHA class, n/N (%) | 0.76 | ||
| I | 18/170 (10) | 9/112 (8) | |
| II | 104/170 (58) | 69/112 (61) | |
| III | 42/170 (24) | 27/112 (24) | |
| IV | 6/170 (3) | 7/112 (6) | |
| Lambda light chain plasma cell dyscrasia, n (%) | 140 (79) | 85 (75) | 0.42 |
| Creatinine (mMol/L) | 103 (81–127) | 106 (84–148) | 0.21 |
| eGFR (mL/min/m2) | 62 (47–83) | 59 (39–74) | 0.1 |
| Proteinuria (g/24h) | 0.6 (0.14–2.35) | 0.4 (0.16–1.5) | 0.52 |
| Serum albumin (g/L) | 37.7 ± 6.8 | 39.0 ± 6.2 | 0.1 |
| Total serum bilirubin (μmol/L) | 10 (7–15) | 12 (9–17) | 0.001 |
| NT-proBNP (ng/L) | 4729 (2243–9949) | 8191 (3856–15 839) | <0.001 |
| NT-proBNP >8500 ng/L, n (%) | 54 (31) | 53 (46) | 0.006 |
| Cardiac troponin T (ng/mL) | 85.5 (48–137) | 104 (67–221) | 0.002 |
| Mayo stage 3, n (%) | 124 (70) | 94 (83) | 0.014 |
| Extra-cardiac organ involvement, n (%) | |||
| Kidney | 85 (48) | 52 (46) | 0.72 |
| Liver | 20 (11) | 12 (11) | 0.87 |
| Autonomic neuropathy | 25 (14) | 19 (17) | 0.52 |
| Peripheral neuropathy | 21 (12) | 20 (18) | 0.16 |
| Gastro-intestinal | 17 (10) | 14 (12) | 0.44 |
| Soft tissues | 66 (37) | 34 (30) | 0.22 |
| Lymph nodes | 2 (1) | NA | 0.26 |
| Lungs | 1 (1) | 2 (2) | 0.32 |
| Number of organs affected, n (%) | 0.61 | ||
| 1 | 36 (20) | 29 (25) | |
| 2 | 75 (42) | 39 (34) | |
| 3 | 46 (26) | 30 (26) | |
| 4 | 15 (8) | 12 (11) | |
| 5 | 5 (3) | 3 (3) | |
| 6 | 1 (1) | 0 (0) | |
| 7 | 0 (0) | 1 (1) | |
| Low QRS voltage, n/N (%) | 81/174 (47) | 59/111 (53) | 0.28 |
| Sinus rhythm, n/N (%) | 138/172 (77) | 93/108 (82) | 0.21 |
| LV septum thickness (mm) | 15 ± 2 | 15 ± 2 | 0.65 |
| LV posterior wall thickness (mm) | 15 ± 2 | 15 ± 2 | 0.95 |
| LV ejection fraction (%) | 52 ± 10 | 48 ± 11 | 0.002 |
| E/E′ ratio | 19 ± 9 | 20 ± 9 | 0.39 |
| S′ wave velocity (lateral wall) (cm/s) | 0.06 (0.05–0.07) | 0.05 (0.04–0.07) | 0.04 |
| LV global longitudinal strain (%) | −12 ± 4 | −10 ± 4 | 0.001 |
| ECV by CMR (%) | 51 ± 10 (n = 42) | 51 ± 8 (n = 19) | 0.83 |
| Native T1 (ms) | 1142 (1106–1161) (n = 46) | 1156 (1106–1176) (n = 21) | 0.36 |
| Transmural pattern of LGE, n/N (%) | 26/45 (58) | 11/19 (58%) | 0.65 |
| Amyloid deposition on 123iSAP scintigraphy, n (%) | |||
| Liver | 30 (17) | 14 (12) | 0.29 |
| Spleen | 75 (42) | 45 (44) | 0.65 |
| Kidney | 33 (19) | 22 (19) | 0.87 |
| Bones | 12 (7) | 12 (11) | 0.25 |
CMR, cardiac magnetic resonance; ECV, extracellular volume; eGFR, estimated glomerular filtration rate; LGE, late gadolinium enhancement; LV, left ventricular; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; SAP, serum amyloid P component.